Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight

Inclusion Criteria:

• Have a confirmed diagnosis of Crohn's disease (CD) or perianal fistulizing CD

• Have obesity body mass index 30 kilograms per meter squared (BMI ≥30 kg/m²), oroverweight (BMI ≥27 kg/m2 to <30 kg/m²) and in the presence of at least 1weight-related comorbid conditions:

• hypertension

• Type 2 diabetes mellitus (T2DM)

• dyslipidemia

• obstructive sleep apnea, or

• cardiovascular disease.

• Have moderately to severely active CD defined by a CDAI score of at least 220 atbaseline.

• Have a centrally read Simple Endoscopic Score for Crohn's Disease (SES-CD) score ≥6for patients with ileal-colonic or ≥4 for patients with isolated ileal diseasewithin 21 days before the first dose of study treatment.

• Participants with a history of CD for ≥8 years involving only or predominantly thecolon must have documented negative results for colorectal dysplasia and cancerwithin 1 year prior to baseline.

• Demonstrated inadequate response, loss of response or intolerance to at least oneprotocol-specified conventional or advanced CD therapy

Exclusion Criteria:

• Have a current diagnosis of Ulcerative Colitis (UC), inflammatory boweldisease-unclassified (formerly known as indeterminate colitis), or primarysclerosing cholangitis.

• Have more than 2 missing segments of the following 5 segments: terminal ileum, ·right colon, transverse colon, ·left colon, and rectum.

• Currently have or are suspected to have an abscess.

• Have a stoma, ileoanal pouch, or ostomy.

• Have a history of more than 3 small bowel resections, total resection of small bowelgreater than 100 centimeters (cm), diagnosis of short bowel syndrome, or anyintestinal or non-intestinal intra-abdominal surgery within 3 months of baseline.

• Have a diagnosis of Type 1 Diabetes Mellitus (T1DM) or have insulin-treated T2DM.

• Have a history of severe hypoglycemia and/or hypoglycemia unawareness within the 6months prior to screening.

• Have had more than 5% body weight change in the past 3 months

• Have a current or recent acute, active infection.